A Trial of Heparin in Patients With Severe Sepsis Who Are Undergoing Treatment With Drotrecogin Alfa (Activated)
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the relative efficacy and safety of prophylactic
heparin co-administration during drotrecogin alfa (activated) infusion in the treatment of
severe sepsis in the adult.
Phase:
Phase 4
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Calcium heparin Dalteparin Drotrecogin alfa activated Heparin Heparin, Low-Molecular-Weight Protein C Tinzaparin